Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs

BACKGROUND: Phase 2a trials in tuberculosis typically use early bactericidal activity (EBA), the decline in sputum CFU over 14 days, as the primary end-point for testing the efficacy of drugs as monotherapy. However, the cost of phase 2a trials can range from USD 7 million to USD 19.6 million on ave...

Descripción completa

Detalles Bibliográficos
Autores principales: Ernest, Jacqueline P., Goh, Janice Jia Ni, Strydom, Natasha, Wang, Qianwen, van Wijk, Rob C., Zhang, Nan, Deitchman, Amelia, Nuermberger, Eric, Savic, Rada M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469274/
https://www.ncbi.nlm.nih.gov/pubmed/37321622
http://dx.doi.org/10.1183/13993003.00165-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469274/
https://www.ncbi.nlm.nih.gov/pubmed/37321622
http://dx.doi.org/10.1183/13993003.00165-2023

Ejemplares similares